Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy

Pharmaceutical Technology· Jonathan Weiss / Shutterstock.
Phalguni Deswal
2 min read
0
In this article:

Japanese pharma company Takeda has signed an exclusive, worldwide option and licence agreement for AC Immune’s amyloid beta-targeting Alzheimer’s disease (AD) immunotherapy, in a deal worth up to $2.2bn.

As per the agreement, AC Immune will receive $100m in upfront payment and will be in line to receive up to $2.1bn in milestone-based payments. The Swiss pharma company will also be eligible to receive “tiered double-digit royalties” should Takeda choose to license the therapy following the completion of the Phase II trial.

Following the news, AC Immune’s stock was up by more than 57% in premarket trading today, compared to the market close on Friday. The company’s market cap stands at $228.5m.

ACI-24.060 targets the toxic forms of amyloid beta protein, which are involved in the pathogenesis of AD. The therapy is designed to induce an antibody response against those amyloid beta versions thereby disrupting plaque formation and disease progression in AD.

AC Immune is evaluating the amyloid beta-targeting immunotherapy in a placebo-controlled Phase Ib/II ABATE trial (NCT05462106) as a treatment for early AD, and the genetic disorder Down syndrome, which is caused due to an extra copy of a chromosome. The company will also be responsible for completing the ABATE trial.

Following its completion, Takeda will have the option to conduct and fund further clinical development. The Japanese company will also bear all global regulatory and commercialisation responsibilities.

In August 2023, Takeda suffered a setback when it terminated the development of its own AD therapy, DNL919 (TAK-920), which was developed in collaboration with Denali Therapeutics. The clinical programme was discontinued due to safety concerns seen in the healthy volunteers who were a part of the Phase I trial (NCT05450549). At the time, Denali said the “safety signals of moderate, reversible haematologic effects” would suggest that the therapy is likely to have a “narrow therapeutic window”.

AC Immune has also partnered with Johnson & Johnson (J&J) to develop an AD therapy dubbed ACI-35.030 (JNJ-64042056). In December 2023, AC Immune announced that J&J plans to start a “potentially registration-enabling”, placebo-controlled Phase IIb ReTain trial evaluating the therapy in preclinical AD patients. The study will enrol approximately 500 patients. The study’s primary endpoint evaluates the participant’s cognitive decline, assessed using the preclinical AD cognitive composite 5 (PACC-5) score.

"Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.


 


The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Advertisement

Recommended Stories

  • The Next Humira? Insmed Catapults 119% On Its 'Very Attractive' Opportunity In Lung Disease.

    Insmed stock catapulted Tuesday after the biotech company's experimental lung disease treatment succeeded in a final-phase study.

  • Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why

    Shares of Moderna (MRNA) are being driven by encouraging pipeline updates and plans for potential product launches.

  • Insmed Stock Surges on Trial Win for Lung-Condition Drug. ‘We Hit the Mark,’ CEO Says.

    Analysts had said shares could more than double if the trial was a success, or fall by more than half if it failed. The drug brensocatib, treats a condition called bronchiectasis.

  • Why Is Inflammatory Diseased-Focused Insmed Stock Soaring On Tuesday?

    Insmed Incorporated (NASDAQ:INSM) shares are trading higher after the company released topline results from the ASPEN Phase 3 study of brensocatib in patients with non-cystic fibrosis bronchiectasis. Non–cystic fibrosis bronchiectasis is a chronic inflammatory condition of the lungs associated with respiratory infections, daily coughing, and sputum. The study met its primary endpoint, with both dosage strengths of brensocatib demonstrating statistically significant reductions in the annualized r

  • Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)

    Editor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead of ‘Lung’ cancer. Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage triple-negative breast cancer (TNBC). The study evaluated Keytruda in combination with chemotherapy as a pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant). The study met its overall survival (OS) endpoint.

  • Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why

    Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.

  • Johnson & Johnson Agrees to Buy Numab Unit, Investigational Skin Disease Treatment For $1.25 Billion

    Johnson & Johnson Agrees to Buy Numab Unit, Investigational Skin Disease Treatment For $1.25 Billion

  • Insmed Shares Rocket After Drug Eases Lung Disease Symptoms

    (Bloomberg) -- Insmed Inc. shares more than doubled after the company’s experimental drug reduced episodes of worsening symptoms in a final-stage study of patients with a rare lung condition. Most Read from BloombergWall Street Moves to Fastest Settlement of Trades in a CenturyTreasuries Hit as US Sales Struggle to Lure Buyers: Markets WrapFor Private Credit’s Top Talent, $1 Million a Year Is Not EnoughIsraeli Airstrike and Egyptian Guard’s Death Ratchet Up TensionsCatering to the Ultra-Rich Is

  • Analysis-Weight-loss drug forecasts jump to $150 billion as supply grows

    As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s. "It is very unusual to have a medicine that is capturing the imagination of millions of people," said Michael Kleinrock, senior research director at healthcare analytics firm IQVIA Institute for Data Science. Most insurers do not cover the new therapies with low co-payments, but an unprecedented percentage of people are paying themselves or with coupons from drug manufacturers, he said.

  • The more Americans who take Ozempic, the faster the US economy could grow, Goldman Sachs says

    With the US obesity rate hovering at around 40%, tens of millions of Americans could take GLP-1 drugs over the next few years.